Centre National De La Recherche Scientifique

Elro Pharma Sarl

Therapeutiques Substitutives

Valbiofrance

Sorbonne Université

Université Paris Est Creteil Val De Marne

Elro Pharma

Jose P Courty

Denis S Barritault

Gilles Guichard

Ara G Hovanessian

Jean Paul Briand

Jean Delbe

Jean-Paul Briand

Robert H Zimmer

Jacqueline Jozefonvicz

Jean-Pierre Caruelle

Yamina Hamma

Jacqueline Jozefonvicz Nee Dorgebray

Josette Badet Nee Genissel

Faouzi Slaoui

Michele Tardieu

Danielle Gulino Nee Debrac

Marie-Anne Dourges Nee Jacquot

Ammar Achour

Pierre Milhiet

Isabelle Pierrot

Haixang Zhang

Annie Lang

Chantal Devin

Khalid Laaroubi

Ara Hovanessian

Johanna Allegonda Van Zoggel

Cecile Galanth

Pierre Nicolas

Mohamed Amiche

Haixiang Zhang

Robert Zimmer

Denis Barritault

A method for treating disorders involving deregulation of cell proliferation and/or angiogenesis comprising the administration of an effective amount of a multivalent synthetic compound comprising a support on which at least 3 pseudopeptide units are grafted, said compound being of formula (I).

Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation

The present invention relates to new optically pure compounds displaying an improved anticancer activity compared to previously known complex mixtures of stereoisomers thereof. Such compounds are of formula (I): wherein each X independently represents any amino acid; n is 0 or 1; m is an integer between 0 and 3; k is an integer of at least 3; Psi is a reduced bond of formula replacing the peptide amide bond between Lys and Pro; and wherein Lys residues in pseudopeptide units of said compound of formula (I) are either all in L configuration or all in D configuration. A method for preparing such compounds, and therapeutic uses thereof are also provided. The synthetic method involves the selective reduction of the peptide bond between Lys and Pro in a dipeptide intermediate with borane. The therapeutic uses are against cancer, inflammation and for wound healing.

Optically pure compounds for improved therapeutic efficiency

A pharmaceutical composition for stimulating production of cytokines of inflammation including a peptide corresponding to formula (I) below:(A)-A1-A1-A2-A1-A3-A4-A1-(A)in which A is any amino acid, n and m are each whole numbers from 0 to 20 whose sum n+m is between 0 and 20, A1 is a basic amino acid and more particularly lysine (Lys) or arginine (Arg), A2 is an amino acid selected from the group consisting of basic amino acids, glutamic acid (Glu), glycine (Gly) and aspartic acid (Asp), A3 is an amino acid selected from the group consisting of basic amino acids, proline (Pro), glutamic acid (Glu) and glutamine (Gln), A4 is an amino acid selected from the group consisting of basic amino acids, glutamic acid (Glu), glycine (Gly), serine (Ser) and valine (Val), and a pharmaceutically acceptable carrier.

Peptides which stimulate the expression of the cytokines of inflammation and promote tissue regeneration

HARP family growth factors

Compositions useful for regenerating cells and tissues comprise at least one functionalized dextran which has been substituted with carboxymethyl, benzylamide, or benzylamide sulfonate. These dextrans can be used alone or in combination with acid or basic fibroblast growth factors to enhance tissue or cell regeneration. Additionally, these dextrans enhance the stability of acid or basic fibroblast growth factors.

Method of regenerating cells and tissues using functionalized dextrans

The present invention relates to the application, as the stationary phase in affinity chromatography for the purification of the FGF type growth factors, of the polymers or copolymers onto which --SO.sub.3 H and --SO.sub.3 M groups are randomly bound, groups in which M denotes a physiologically acceptable metal, as well as, preferably, --SO.sub.2 R groups, in which R denotes a radical obtained by removal of a hydrogen atom from the amino group of an amino acid or an amino acid derivative. The invention relates also to the obtaining of a purified bFGF or aFGF growth factor, or a mixture of these growth factors, consisting in carrying out an affinity chromatography on a resin such as defined hereinabove, by carrying out an elution with a neutral pH buffer having an ionic strength equivalent to that of a 0.15 M to 2.5 M NaCl solution.

Application of resins consisting of functional polymers as the

Growing community of inventors

Villecresnes, France

Jose P Courty